相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。LUF7244, an allosteric modulator/activator of Kv11.1 channels, counteracts dofetilide-induced torsades de pointes arrhythmia in the chronic atrioventricular block dog model
Muge Qile et al.
BRITISH JOURNAL OF PHARMACOLOGY (2019)
The Pore-Lipid Interface: Role of Amino-Acid Determinants of Lipophilic Access by Ivabradine to the hERG1 Pore Domain
Laura Perissinotti et al.
MOLECULAR PHARMACOLOGY (2019)
Molecular Basis of Altered hERG1 Channel Gating Induced by Ginsenoside Rg3
Alison Gardner et al.
MOLECULAR PHARMACOLOGY (2017)
Cryo-EM Structure of the Open Human Ether-a-go-go-Related K+ Channel hERG
Weiwei Wang et al.
CELL (2017)
Allosteric Modulation of Kv11.1 (hERG) Channels Protects Against Drug-Induced Ventricular Arrhythmias
Zhiyi Yu et al.
CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY (2016)
A new hERG allosteric modulator rescues genetic and drug-induced long-QT syndrome phenotypes in cardiomyocytes from isogenic pairs of patient induced pluripotent stem cells
Luca Sala et al.
EMBO MOLECULAR MEDICINE (2016)
New potential binding determinant for hERG channel inhibitors
P. Saxena et al.
SCIENTIFIC REPORTS (2016)
Safety pharmacology studies using EFP and impedance
Alison Obergrussberger et al.
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS (2016)
A 2015 focus on preventing drug-induced arrhythmias
A. Bossu et al.
EXPERT REVIEW OF CARDIOVASCULAR THERAPY (2016)
NS1643 Interacts around L529 of hERG to Alter Voltage Sensor Movement on the Path to Activation
Jiqing Guo et al.
BIOPHYSICAL JOURNAL (2015)
Synthesis and biological evaluation of negative allosteric modulators of the Kv11.1(hERG) channel
Zhiyi Yu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2015)
HERG1 channel agonists and cardiac arrhythmia
Michael C. Sanguinetti
CURRENT OPINION IN PHARMACOLOGY (2014)
Allosteric modulators of the hERG K+ channel Radioligand binding assays reveal allosteric characteristics of dofetilide analogs
Zhiyi Yu et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2014)
Large-scale mutational analysis of Kv11.1 reveals molecular insights into type 2 long QT syndrome
Corey L. Anderson et al.
NATURE COMMUNICATIONS (2014)
International Union of Basic and Clinical Pharmacology. XC. Multisite Pharmacology: Recommendations for the Nomenclature of Receptor Allosterism and Allosteric Ligands
Arthur Christopoulos et al.
PHARMACOLOGICAL REVIEWS (2014)
Structure-activity relationships of pentamidine-affected ion channel trafficking and dofetilide mediated rescue
R. Varkevisser et al.
BRITISH JOURNAL OF PHARMACOLOGY (2013)
Inhibiting the clathrin-mediated endocytosis pathway rescues KIR2.1 downregulation by pentamidine
Rosanne Varkevisser et al.
PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY (2013)
Cardiac ion channel trafficking defects and drugs
Kathy C. G. de Git et al.
PHARMACOLOGY & THERAPEUTICS (2013)
Drug-induced functional cardiotoxicity screening in stem cell-derived human and mouse cardiomyocytes: Effects of reference compounds
Herbert M. Himmel
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS (2013)
ICA-105574 Interacts with a Common Binding Site to Elicit Opposite Effects on Inactivation Gating of EAG and ERG Potassium Channels
Vivek Garg et al.
MOLECULAR PHARMACOLOGY (2013)
hERG K+ CHANNELS: STRUCTURE, FUNCTION, AND CLINICAL SIGNIFICANCE
Jamie I. Vandenberg et al.
PHYSIOLOGICAL REVIEWS (2012)
Molecular Determinants of Pentamidine-Induced hERG Trafficking Inhibition
Adrienne T. Dennis et al.
MOLECULAR PHARMACOLOGY (2012)
Inhibition of lysosomal degradation rescues pentamidine-mediated decreases of KIR2.1 ion channel expression but not that of Kv11.1
Lukas Nalos et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2011)
CHARMM General Force Field: A Force Field for Drug-Like Molecules Compatible with the CHARMM All-Atom Additive Biological Force Fields
K. Vanommeslaeghe et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2010)
Revealing the structural basis of action of hERG potassium channel activators and blockers
Matthew Perry et al.
JOURNAL OF PHYSIOLOGY-LONDON (2010)
Pharmacological Removal of Human Ether-a-go-go-Related Gene Potassium Channel Inactivation by 3-Nitro-N-(4-phenoxyphenyl) Benzamide (ICA-105574)
Aaron C. Gerlach et al.
MOLECULAR PHARMACOLOGY (2010)
Docking Model of Drug Binding to the Human Ether-a-go-go Potassium Channel Guided by Tandem Dimer Mutant Patch-Clamp Data: A Synergic Approach
Yumi N. Imai et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Software news and updates - CHARNIM-GUI: A web-based grraphical user interface for CHARMM
Sunhwan Jo et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2008)
Structural basis of action for a human ether-a-go-go-related gene 1 potassium channel activator
Matthew Perry et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Canonical sampling through velocity rescaling
Giovanni Bussi et al.
JOURNAL OF CHEMICAL PHYSICS (2007)
Molecular determinants of hERG channel block
K Kamiya et al.
MOLECULAR PHARMACOLOGY (2006)
hERG potassium channels and cardiac arrhythmia
MC Sanguinetti et al.
NATURE (2006)
Mechanism of action of a novel human ether-a-go-go-related gene channel activator
O Casis et al.
MOLECULAR PHARMACOLOGY (2006)
Most LQT2 mutations reduce Kv11.1 (hERG) current by a class 2 (trafficking-deficient) mechanism
CL Anderson et al.
CIRCULATION (2006)
Pentamidine reduces hERG expression to prolong the QT interval
JS Cordes et al.
BRITISH JOURNAL OF PHARMACOLOGY (2005)
Pentamidine-induced long QT syndrome and block of hERG trafficking
YA Kuryshev et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Pharmacological rescue of human K+ channel long-QT2 mutations -: Human ether-a-go-go-related gene rescue without block
S Rajamani et al.
CIRCULATION (2002)
The binding site for channel blockers that rescue misprocessed human long QT syndrome type 2 ether-a-gogo-related gene (HERG) mutations
E Ficker et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
分享论文
